Literature DB >> 26740856

Morvan Syndrome: A Case Report With Patient Narrative and Video.

Mark Maskery1, Suresh K Chhetri2, Rejith Dayanandan2, Claire Gall2, Hedley C A Emsley3.   

Abstract

A 74-year-old gentleman was admitted to the regional neurosciences center with encephalopathy, myokymia, and dysautonomia. Chest imaging had previously identified an incidental mass in the anterior mediastinum, consistent with a primary thymic tumor. Antivoltage-gated potassium channel (anti-VGKC) antibodies were positive (titer 1273 pmol/L) and he was hypokalemic. Electromyogram and nerve conduction studies were in keeping with peripheral nerve hyperexcitability syndrome, and an electroencephalogram was consistent with encephalopathy. A diagnosis of Morvan syndrome was made, for which he was initially treated with high-dose steroids, followed by a 5-day course of intravenous immunoglobulin (IVIG) therapy. He also underwent thymectomy, followed by a postexcision flare of his symptoms requiring intensive care management. Further steroids, plasmapheresis, and IVIG achieved stabilization of his clinical condition, enabling transfer for inpatient neurorehabilitation. He was commenced on azathioprine and a prolonged oral steroid taper. A subsequent presumed incipient relapse responded well to further IVIG treatment. This case report documents a thymoma-associated presentation of anti-VGKC-positive Morvan syndrome supplemented by patient and carer narrative and video, both of which provide valuable further insights into this rare disorder. There are a limited number of publications surrounding this rare condition available in the English literature. This, combined with the heterogenous presentation, association with underlying malignancy, response to treatment, and prognosis, provides a diagnostic challenge. However, the association with anti-VGKC antibody-associated complexes and 2 recent case series have provided some scope for both accurate diagnosis and management.

Entities:  

Keywords:  electromyogram/nerve conduction studies; general neurology; neurooncology

Year:  2016        PMID: 26740856      PMCID: PMC4680894          DOI: 10.1177/1941874415580597

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  13 in total

1.  Morvan's syndrome: clinical, laboratory, and in vitro electrophysiological studies.

Authors:  Wolfgang N Löscher; Julia Wanschitz; Karlheinz Reiners; Stefan Quasthoff
Journal:  Muscle Nerve       Date:  2004-08       Impact factor: 3.217

2.  Sub-acute presentation of Morvan's syndrome after thymectomy.

Authors:  D A Cottrell; K J Blackmore; P R W Fawcett; D Birchall; A Vincent; S Barnard; T J Walls
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 3.  Morvan syndrome: a case report and review of the literature.

Authors:  Elias Abou-Zeid; Lana Jeradeh Boursoulian; Walter S Metzer; Betul Gundogdu
Journal:  J Clin Neuromuscul Dis       Date:  2012-06

Review 4.  Neurophysiologic studies in Morvan syndrome.

Authors:  Keith A Josephs; Michael H Silber; Robert D Fealey; Todd B Nippoldt; Raymond G Auger; Steven Vernino
Journal:  J Clin Neurophysiol       Date:  2004 Nov-Dec       Impact factor: 2.177

5.  Course and outcome of a voltage-gated potassium channel antibody negative Morvan's syndrome.

Authors:  Carlo Rinaldi; Cinzia Valeria Russo; Alessandro Filla; Giuseppe De Michele; Enrico Marano
Journal:  Neurol Sci       Date:  2009-03-04       Impact factor: 3.307

6.  Long-term clinical course with voltage-gated potassium channel antibody in Morvan's syndrome.

Authors:  Nam-Hee Kim; Angela Vincent; Saroshi R Irani; Sang Eun Kim; Kwang-Woo Lee; Kyung Seok Park
Journal:  J Neurol       Date:  2013-07-28       Impact factor: 4.849

7.  An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre.

Authors:  S Huda; S H Wong; P Pettingill; D O'Connell; A Vincent; M Steiger
Journal:  J Neurol       Date:  2014-11-27       Impact factor: 4.849

8.  Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex.

Authors:  Panayiotis Loukaides; Natasa Schiza; Philippa Pettingill; Lakis Palazis; Emmelia Vounou; Angela Vincent; Kleopas A Kleopa
Journal:  J Neurol Sci       Date:  2011-09-08       Impact factor: 3.181

9.  fasciculations, autonomic symptoms and limbic encephalitis: a thymoma-associated Morvan's-like syndrome.

Authors:  Feza Deymeer; Sukriye Akca; Gulsen Kocaman; Yesim Parman; Piraye Serdaroglu; Oget Oktem-Tanor; Oguzhan Coban; Angela Vincent
Journal:  Eur Neurol       Date:  2006-01-06       Impact factor: 1.710

10.  Clinical, laboratory and electrophysiological features of Morvan's fibrillary chorea.

Authors:  Will Lee; Timothy J Day; David R Williams
Journal:  J Clin Neurosci       Date:  2013-05-24       Impact factor: 1.961

View more
  4 in total

1.  Morvan's syndrome-is a pathogen behind the curtain?

Authors:  Rohit Singh; Pritam Das; Upinder Kaur; Anamika Misra; Ashis Choudhury; Sukdev Manna; Rohit Gaude; Deepak Gautam; Indrajeet Singh Gambhir; Sankha Shubhra Chakrabarti
Journal:  Neurol Sci       Date:  2018-08-09       Impact factor: 3.307

2.  Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report.

Authors:  Edvina Galié; Rosaria Renna; Domenico Plantone; Andrea Pace; Mirella Marino; Bruno Jandolo; Tatiana Koudriavtseva
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

Review 3.  Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes.

Authors:  Cheran Elangovan; Adeolu Morawo; Aiesha Ahmed
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.972

4.  Morvan Syndrome Converted from Isaacs' Syndrome after Thymectomy with Positivity for Both Anti-LGI1 and Anti-CASPR2 Antibodies.

Authors:  Daisuke Suzuki; Yoshihiro Suzuki; Daisuke Sato; Kenji Kikuchi; Naoki Kanauchi; Akiko Nishida; Yasuyuki Ohta
Journal:  Intern Med       Date:  2021-10-19       Impact factor: 1.282

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.